Active agents targeting key bacterial interactions that initiate biofilm formation in the oral cavity, may alter periodontitis progression; however, to date, specifically-targeted prophylactic and treatment strategies have been limited. Previously we developed a peptide, BAR (SspB Adherence Region), that inhibits oral P. gingivalis/S. gordonii biofilm formation in vitro and in vivo, and BAR nanoparticles that increase BAR effectiveness via multivalency and prolonged delivery. However, limited BAR loading and nanoparticle retention in the oral cavity can result in inadequate release and efficaciousness. Given this, an effective delivery platform that can release concentrations of BAR suitable for twice-daily applications, may offer an alternative that enhances loading, ease of administration, and retention in the oral cavity. With this in mind, the study objectives were to develop and characterize a rapid-release platform, composed of polymeric electrospun fibers (EFs) that encapsulate BAR, and to evaluate fiber safety and functionality against P. gingivalis/S. gordonii biofilms in vitro. Poly(lactic-co-glycolic acid) (PLGA), poly(L-lactic acid) (PLLA), and polycaprolactone (PCL) were electrospun alone or blended with polyethylene oxide (PEO), to provide high BAR loading and rapid-release. The most promising formulation, 10:90 PLGA:PEO EFs, provided 95% BAR release after 4 h, dose-dependent inhibition of biofilm formation (IC50 = 1.3 μM), disruption of established dual-species biofilms (IC50 = 2 μM), and maintained high cell viability. These results suggest that BAR-incorporated EFs may provide a safe and specifically-targeted rapid-release platform to inhibit and disrupt dual-species biofilms, that we envision may be applied twice-daily to exert prophylactic effect in the oral cavity.
Keywords: Porphyromonas gingivalis; Streptococcus gordonii; electrospun fibers; oral biofilm; peptide delivery; periodontal disease.
Copyright © 2020 Mahmoud, Sapare, Curry, Demuth and Steinbach-Rankins.
BAR-encapsulated nanoparticles for the inhibition and disruption of Porphyromonas gingivalis-Streptococcus gordonii biofilms.J Nanobiotechnology. 2018 Sep 15;16(1):69. doi: 10.1186/s12951-018-0396-4. J Nanobiotechnology. 2018. PMID: 30219060 Free PMC article.
Peptide-modified nanoparticles inhibit formation of Porphyromonas gingivalis biofilms with Streptococcus gordonii.Int J Nanomedicine. 2017 Jun 22;12:4553-4562. doi: 10.2147/IJN.S139178. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28790818 Free PMC article.
Functional assessment of peptide-modified PLGA nanoparticles against oral biofilms in a murine model of periodontitis.J Control Release. 2019 Mar 10;297:3-13. doi: 10.1016/j.jconrel.2019.01.036. Epub 2019 Jan 25. J Control Release. 2019. PMID: 30690103 Free PMC article.
Dual lifestyle of Porphyromonas gingivalis in biofilm and gingival cells.Microb Pathog. 2016 May;94:42-7. doi: 10.1016/j.micpath.2015.10.003. Epub 2015 Oct 9. Microb Pathog. 2016. PMID: 26456558 Review.
Relating Advanced Electrospun Fiber Architectures to the Temporal Release of Active Agents to Meet the Needs of Next-Generation Intravaginal Delivery Applications.Pharmaceutics. 2019 Apr 3;11(4):160. doi: 10.3390/pharmaceutics11040160. Pharmaceutics. 2019. PMID: 30987206 Free PMC article. Review.